Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: A longitudinal analysis

The Lancet Global Health

Volumn 2, Issue 1, 2014, Pages

  Farahani, Mansour ^a   Vable, Anusha ^a   Lebelonyane, Refeletswe ^b   Seipone, Khumo ^b   Anderson, Marina ^b   Avalos, Ava ^b   Chadborn, Tim ^b   Tilahun, Hailu ^a   Roumis, Danae ^a   Moeti, Themba ^c   Musuka, Godfrey ^c   Busang, Lesego ^c   Gaolathe, Tendani ^d   Malefho, Kolaatamo C S ^b   Marlink, Richard ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of HIV AIDS Prevention and Care   (Botswana)

^c African Comprehensive HIV/AIDS Partnerships   (Botswana)

^d BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VIRUS LOAD; BOTSWANA; EPIDEMIOLOGY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LONGITUDINAL STUDY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; BOTSWANA; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; VIRAL LOAD; YOUNG ADULT;

EID: 84890854370     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(13)70149-9     Document Type: Article

References (32)

1. Stover J, Fidzani B, Molomo BC, Moeti T, Musuka G Estimated HIV trends and program effects in Botswana. PLoS One 2008, 3:e3729.
2. Monitoring and evaluation unit monthly report 2013, Botswana Ministry of Health, Ministry of Health, Gabarone.
3. Ivers LC, Kendrick D, Doucette K Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005, 41:217-224.
4. Abaasa AM, Todd J, Ekoru K, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res 2008, 8:241.
5. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008, 300:506-507.
6. Chasombat S, McConnell MS, Siangphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009, 50:506-512.
7. Rosen S, Fox MP, Gill CJ Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007, 4:e298.
8. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367:1335-1342.
9. Global report: UNAIDS report on the global AIDS epidemic UNAIDS, (accessed March 21, 2013). http://www.unaids.org/en/resources/publications/2012/name,76121,en.asp.
10. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008, 8:678-687.
11. Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008, 371:752-759.
12. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782-793.
13. Yiannoutsos CT, An MW, Frangakis CE, et al. Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One 2008, 3:e3843.
14. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009, 151:241-251. W52.
15. Weigel R, Estill J, Egger M, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 2012, 26:365-373.
16. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002, 360:34-40.
17. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353:2325-2334.
18. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008, 22:2303-2311.
19. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008, 8:52.
20. Lowrance DW, Ndamage F, Kayirangwa E, et al. Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr 2009, 52:49-55.
21. Antiretroviral therapy for HIV infections in adults and adolescents: recommendations for a public health approach. 2006 revision 2006, WHO, World Health Organization, Geneva.
22. Brinkhof MW, Pujades-Rodriguez M, Egger M Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009, 4:e5790.
23. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 2008, 3:e1725.
24. HIV and AIDS estimates 2012: Botswana UNAIDS, (accessed May 20, 2013). http://www.unaids.org/en/regionscountries/countries/botswana/.
25. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010, 24:2263-2270.
26. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006, 20:1181-1189.
27. Djomand G, Greenberg AE, Sassan-Morokro M, et al. The epidemic of HIV/AIDS in Abidjan, Cote d'lvoire: a review of data collected by projet RETRO-CI from 1987 to 1993. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:358-365.
28. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908.
29. Marazzi MC, Liotta G, Germano P, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 2008, 24:555-560.
30. Fox MP, Rosen S Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010, 15:1-15.
31. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat 2011, 2011:463704.
32. De Cock K, Adjorlolo G, Ekpini E, et al. Epidemiology and transmission of HIV-2: why there is no HIV-2 pandemic?. JAMA 1993, 270:2083-2086.